Trial Profile
The investigation of the efficacy of insulin glargine [sanofi-aventis] on glycemic control when combined with either repaglinide [Novo Nordisk] or acarbose [Bayer] in obese Type 2 diabetic patients
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 09 Jul 2009
Price :
$35
*
At a glance
- Drugs Acarbose (Primary) ; Insulin glargine (Primary) ; Repaglinide (Primary)
- Indications Type 2 diabetes mellitus
- Focus Therapeutic Use
- 09 Jul 2009 New trial record.